Literature DB >> 22682825

Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

Patrick C Walsh.   

Abstract

Entities:  

Year:  2012        PMID： 22682825     DOI： 10.1016/j.juro.2012.03.102

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  2 in total

Review 1.  Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial.

Authors:  Mark A Moyad; Mark C Scholz
Journal:  Res Rep Urol       Date:  2014-07-16

2.  TRIM16 suppresses the progression of prostate tumors by inhibiting the Snail signaling pathway.

Authors:  Li Qi; Zhong Lu; Yong-Hong Sun; Hai-Tao Song; Wei-Kang Xu
Journal:  Int J Mol Med       Date:  2016-10-17       Impact factor: 4.101
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.